Amundi Acquires New Shares in Corcept Therapeutics Incorporated $CORT
Amundi acquired 11,392 shares of Corcept Therapeutics (CORT) in the first quarter, valued at $459,000, adding to the 93.61% institutional ownership of the company. Despite significant insider selling totaling $33.15 million over the past 90 days, Corcept reported strong quarterly earnings of $0.36 EPS, …